TRDA (Entrada Therapeutics) Current Accrued Expense: $7.71 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRDA Entrada Therapeutics Inc TRDA
32 GF Score
Price $7.13
GF Value $0.39
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Entrada Therapeutics Current Accrued Expense?

Entrada Therapeutics TRDA -0.42% 32 Current Accrued Expense is $7.71 Mil as of Jun. 2026. GuruFocus rates TRDA with a GF Score™ of 32/100 and a GF Value™ of $0.39 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Entrada Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $7.71 Mil.

Entrada Therapeutics's quarterly Current Accrued Expense declined from Dec. 2025 ($8.46 Mil) to Mar. 2026 ($0.00 Mil) but then increased from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($7.71 Mil).

Entrada Therapeutics's annual Current Accrued Expense increased from Dec. 2023 ($3.66 Mil) to Dec. 2024 ($4.91 Mil) and increased from Dec. 2024 ($4.91 Mil) to Dec. 2025 ($8.46 Mil).

Entrada Therapeutics Current Accrued Expense Related Terms

Entrada Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Entrada Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entrada Therapeutics Current Accrued Expense Chart

Entrada Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 1.45 2.08 3.66 4.91 8.46

Entrada Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.10 7.86 8.46 0.00 7.71
TRDA
32GF Score
Entrada Therapeutics Inc TRDA
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entrada Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $7.71 Mil mean?
Entrada Therapeutics (TRDA) has a Current Accrued Expense of $7.71 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Entrada Therapeutics and its competitors.
Is Entrada Therapeutics' Current Accrued Expense too high?
Entrada Therapeutics' current Current Accrued Expense is $7.71 Mil. Overall, Entrada Therapeutics has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Current Accrued Expense compare to PYXS and AVXL?
Entrada Therapeutics' Current Accrued Expense of $7.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Entrada Therapeutics and its competitors. Entrada Therapeutics's current Current Accrued Expense is $7.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $7.13 — trading 1728.2% above its estimated fair value. The current Current Accrued Expense is $7.71 Mil. Entrada Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Current Accrued Expense is $7.71 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Entrada Therapeutics (TRDA) Overvalued in 2026?

Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued. The current stock price of $7.13 is trading 1728.2% above its estimated GF Value™ of $0.39. GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.

Key valuation signals for TRDA:

  • Current Accrued Expense: $7.71 Mil
  • GF Value™: $0.39 vs. price of $7.13 (1728.2% above fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entrada Therapeutics Business Description

Address One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
32GF Score

Get the complete analysis for TRDA

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.13
Price
$0.39
GF Value